Viral Hepatitis Laboratory, Oswaldo Cruz Foundation, FIOCRUZ, Rua Leopoldo Bulhões 1480, Rio de Janeiro, CEP 21041-210, Brazil.
Arch Virol. 2010 May;155(5):807-11. doi: 10.1007/s00705-010-0642-z. Epub 2010 Apr 20.
The prevalence of naturally occurring mutations in hepatitis C virus associated with resistance to protease inhibitors in chronically infected patients has not been reported in Brazil. The NS3 serine protease domain was sequenced in 114 therapy-naïve patients infected with subtype 1a (n = 48), 1b (n = 53), or 3a (n = 13). A V36L mutation was observed in 5.6% patients infected with subtype 1b and in all isolates of the 3a subtype, and a T54S mutation was detected in 4.1% of isolates of subtype 1a. In conclusion, the presence of variants carrying mutations associated with resistance to protease inhibitors in therapy-naïve patients may be important for future therapeutic strategies.
在巴西，尚未报道慢性感染患者中与蛋白酶抑制剂耐药相关的丙型肝炎病毒自然发生突变的流行情况。对 114 例未经治疗的感染 1a 型（n = 48）、1b 型（n = 53）或 3a 型（n = 13）的患者的 NS3 丝氨酸蛋白酶结构域进行了测序。观察到携带与蛋白酶抑制剂耐药相关的突变的病毒在 5.6%的 1b 型感染患者和所有 3a 型分离株中存在，而在 4.1%的 1a 型分离株中检测到 T54S 突变。总之，在未经治疗的患者中存在携带与蛋白酶抑制剂耐药相关的变异体可能对未来的治疗策略很重要。
